

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ALLIA.143CP2APPLICATION NO.
09/111,123INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Zaghouni, HabibFILING DATE
July 6, 1998GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	5,508,386	4/96	Zanetti et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	90/02017	7/91	Great Britain				

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PN ↓ PN	1.	Rudikoff et al., <i>Proc. Natl. Sci. USA</i> 179:1979 (1982)
	2.	Panka et al., <i>Proc. Natl. Sci. USA</i> 85:3080-3084 (1988)
	3.	Livingstone et al., <i>Ann. Rev. Immuno.</i> 5:477-501 (1987)
	4.	Hurtenbach et al., <i>J. Exp. Medicine</i> 177:1499-1504 (1993)
	5.	Legge et al., <i>J. Exp. Medicine</i> 185(6):1043-1053 (1997)

EXAMINER	Patricia J. J. J.	DATE CONSIDERED	1/2/01
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.			

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ALLIA.143CP2APPLICATION NO.
09/111,123INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Zaghouani, HabibFILING DATE
July 6, 1998GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

6.	Kuchroo et al., <i>Cellular and Molecular Biology</i> 40(Suppl):21-30 (1994)
7.	Liu, et al., <i>J. Clin. Invest.</i> 98(9):2001-2007 (1996)

EXAMINER

Patman J. Ndz

DATE CONSIDERED

1/02/01

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
ALLIA.143CP2APPLICATION NO.
09/111,123INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
Habib ZaghouniFILING DATE
07/06/98GROUP
1644

USE SEVERAL SHEETS IF NECESSARY)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
PN	A	Liu, C. et al. (1996) FcγRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes. J. Clin. Invest. 98(9):2001-2007. ✓
PN	B	Min, B. et al. (1998) Neonatal exposure to a self-peptide-immunoglobulin chimera circumvents the use of adjuvant and confers resistance to autoimmune disease by a novel mechanism involving interleukin 4 lymph node deviation and interferon γ-mediated splenic anergy. J. Exp. Med. 188(11):2007-2017
PN	C	(03/08/00) PCT International Search Report in 6 pages. Courtesy Copy. ↵

S:\DOCS\JJM\JJM-3967.DOC\060100

EXAMINER	<i>Patricia J. Lator</i>	DATE CONSIDERED	<i>1/02/01</i>
----------	--------------------------	-----------------	----------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.